FindTrial
Sign In

Low-Dose Linperlisib Achieves Rapid Hematological Response in a Patient With Pure Red Cell Aplasia and Moderate-to-Severe Renal Insufficiency: A Case Report

Low-Dose Linperlisib Achieves Rapid Hematological Response in a Patient With Pure Red Cell Aplasia and Moderate-to-Severe Renal Insufficiency: A Case Report

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07900282
Enrollment
1
Registered
2026-10-28
Start date
2026-01-31
Completion date
2026-01-31
Last updated
2026-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Linperlisib, PRCA, Moderate-to-Severe Renal Insufficiency

Keywords

linperlisib, PRCA, Moderate-to-Severe Renal Insufficiency

Brief summary

This article reports a case of a 70-year-old male patient diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL)-associated pure red cell aplasia (PRCA) complicated by moderate-to-severe renal insufficiency. The patient was refractory or intolerant to multiple prior treatment lines, including cyclosporine A, tacrolimus plus prednisone, sirolimus, and cyclophosphamide, and was transfusion-dependent. In this case,we choose the low-dose linperlisib.

Interventions

DRUGlinperlisib

linperlisib 20mg qd

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

* People who diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL)-associated pure red cell aplasia (PRCA). * People who treatmented by linperlisib.

Exclusion criteria

* People who refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
hemoglobin2、4、8weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Oct 29, 2026